1 / 39

Jie Qian National Heart Center & FuWai Hospitall

FFR in Diffuse Multivessel Disease. Jie Qian National Heart Center & FuWai Hospitall. Different Patients with the same symptom : angina. Angio-based PCI. IVUS –based or FFR –Based PCI ?. Why do we need functional evaluation ?. Limitations of coronary angiography

avidan
Download Presentation

Jie Qian National Heart Center & FuWai Hospitall

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. FFR in Diffuse Multivessel Disease Jie Qian National Heart Center & FuWai Hospitall

  2. Different Patients with the same symptom : angina Angio-based PCI IVUS –based or FFR –Based PCI ?

  3. Why do we need functional evaluation ? • Limitations of coronary angiography • Limitations of noninvasive techniques • Cost issues ( Cost / Benefit )

  4. Limitations of Angiography : “Lumengram”: Disconnection with function & physiology

  5. FAME study: (dis)congruence between QCA and FFR Key paper: Tonino et al; JACC 2010; 55: 2816-2821

  6. “I do not stent lesions of 50-70%” You are under-treating 40% of your patients “I always stent lesions of 50-70%” You are over-treating 60% of your patients “I only stent lesions > 70%” You are still over-treating 20% of your patients IVUS does not solve this problem ! (Key publication: Kang, Park, et al: Circulation Cardiov Interv 2011; 4: 65-71)

  7. Limitations of noninvasive techniques • Often not performed • Can be inaccurate in multivessel disease • Generally “territory” specific, but not “vessel” specific • Can be “vessel” specific “ but not “lesion “ specific

  8. Limitations of noninvasive techniques 143 patients with angiographically significant 3-vessel disease ( > 70% diameter stenosis) Tallium Scan Findings % Lima et al , J Am Cll Cardiol 2003; 42:63-70

  9. 75 yrs male, Hyperlipidemia .Hypertension and diabetes Typical chest pain on exerction despite optimal medical therapy . Stress Rest Infero-lateral inducible ischemia

  10. FFR= 0.72 FFR= 0.97 FFR= 0.82 Following stent implantation at prox LCX

  11. Functional Evaluation is not mandatory for every patient :

  12. Intermediate Lesion : Chest pain , without non invasive ischemic test Simple functional evaluation would provide better management …

  13. The angio-guided approach : is it the optimal approach ?

  14. Anatomic Scoring For Each Lesion Segment Location Length Calcification Tortuosity Bifurcation Diffuse Disease Occlusion Thrombus SYNTAX Score SYNTAX Score = 41 SYNTAX Score = 18

  15. CABG(n=171) TAXUS™ Express2™ Stent (n=181) 40 20 Cumulative Event Rate (%) 0 0 6 12 Months Since Allocation MACCE to 12 Months by SYNTAX Score™ TercileLow Scores (0-22) 3VD Subset P=0.66* 17.3% 15.2% Presenter: See Glossary Event Rate ± 1.5 SE, *Fisher exact test Calculated by core laboratory; ITT population

  16. CABG(n=208) TAXUS™ Express2™ Stent (n=207) 40 20 Cumulative Event Rate (%) 0 0 6 12 Months Since Allocation MACCE to 12 Months by SYNTAX Score™ TercileIntermediate Scores (23-32) 3VD Subset P=0.02* 18.6% 10.0% Presenter: See Glossary Event Rate ± 1.5 SE, *Fisher exact test Calculated by core laboratory; ITT population

  17. CABG(n=166) TAXUS™ Express2™ Stent (n=155) 40 20 Cumulative Event Rate (%) 0 0 6 12 Months Since Allocation MACCE to 12 Months by SYNTAX Score™ TercileHigh Scores (33) 3VD Subset P=0.002* 21.5% 8.8% Presenter: See Glossary Event Rate ± 1.5 SE, *Fisher exact test Calculated by core laboratory; ITT population

  18. Stent Number and Length Higher in the SYNTAX Trial 48% of patients received ≥5 stents Max # 14 stents! Multivessel disease:96.2%* 3-vessel disease: 90.8% Avg. stents per patient:4.6 ± 2.3 Avg. stented length: 86.1 mm Patients (%) Total Number of Stents Implanted per Patient *3VD+LM/3VD+LM/2VD+LM/1VD

  19. Linear Increase in MACCE by Number of Stentsin the SYNTAX Trial 1.5 Stents“Typical” Real World Average Avg. in pts with 5-8+ stents in SYNTAX19.6% 4.6 StentsSYNTAX Average 17.8% 1 stent 5.6% 12m MACCE Probability 12m MACCE Rate 12m MACCE in TAXUS Arm 1 2 3 4 5 6 7 8 1 2 3 4 5 6 7 8+ Number of Stents Implanted

  20. Functional SYNTAX Score • 497 patients , FFR-guided arm of FAME Study • 2-3 vessel disease • Angio Syntax Score : Conventional fashion • Functional ( FFR) Syntax Score : counting only the lesions with FFR < 0.80 Functional ( FFR ) SYNTAX Angio SYNTAX FFR reclassifies > 30% ! Fearon WF et al , TCT-MD 2011

  21. Funtctional SYNTAX Score desciminates Risk of Death/MI and Risk of Total MACE Total MACE Death / MI Fearon WF et al , TCT-MD 2011

  22. Is it safe to defer treatment ?

  23. DEFER Study : 5-year Follow-up ( Death / MI )

  24. Risk of deferring PCI if FFR < 0.75 % p<0.05 MACE at 1 year Chamuleau et al , AJC 2002;89:377-80

  25. FFR-Guided PCI in Multivessel Disease 137 patients , non-randomized Wongpraparut et al , AJC 2005; 96:877-884

  26. Patient with stenoses ≥ 50% in at least 2 of the 3 major epicardial vessels Indicate all stenoses ≥ 50% considered for stenting Randomization FFR-guided PCI Angiography-guided PCI Measure FFR in all indicated stenoses Stent only those stenoses with FFR ≤ 0.80 Stent all indicated stenoses 1-year follow-up FLOW CHART

  27. FAME study: PRIMARY ENDPOINT Composite of death, myocardial infarction, or repeat revascularization (“MACE”) at 1 year

  28. FAME study: Adverse Events at 1 year

  29. FFR-guided FAME study: Event-free Survival absolute difference in MACE-free survival 30 days 2.9% 90 days 3.8% Angio-guided 180 days 4.9% 360 days 5.3%

  30. Adverse Events at 2 Years

  31. FAME study: 2-year Event-free Survival

  32. Stent length / Number of stent & restenosis – stent thrombosis

  33. Stent Length is Independent Predictor of Restenosis. Lee CW et al. Am J Cardiol 2006;97:506-511 % P<0.001 mm

  34. Non-Q-Wave MI Data from DES studies suggest Non-Q-Wave MI rates increase as total stented length increases. 25mm 30mm 40 mm TAXUS stent Cyphert stent TAXUS V Multiple stents 7.3 Non Q wave MI 15 mm Mean Stent length ( mm) 65 mm

  35. Full Metal Jacket.Ielasi, Colombo et al. Ital J Inv Cardiol 2009; 3 Suppl: 111 • 658 full metal jacket lesions (≥60mm) in 617 patients. • 33% DM, 33 had prior PCI, 33% CTO. • 39 months mean follow up (2 yr in 91% pts). • Mortality 7.3% • MI during follow up: 3.5% • TLR: 23.4% • Stent thrombosis (Def or Probable): 2.6% (10/17 while on DAP).

  36. Longer Stents have more Thrombosis. Roy et al. AJC 2009; 803:801-5 • Independent Predictors of Cumulative ST. • ISRS (OR 2.7, p<0.001) • Number of stents (OR 1.7, p<0.001) • Clopridogrel Cessation (OR 1.7, p<0.001) • Diabetes (OR 1.5, p 0.2) • Renal Insufficiency (OR 1.4, p 0.4)

  37. Conclusions • Pressure wire assessment in MVD and diffuse disease is technically easy and offers more accurate functional evaluation of coronary stenoses. • Defering treatment of intermediate lesions when the FFR>0.80 seems safe and effective • Reducing the number and length of stents /vessel and or /patient is translated in less MACE on long term outcome

  38. THANKS!

More Related